Our clinical trials

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01).

Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.

HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

A FRENCH, PROSPECTIVE, NON-INTERVENTIONAL RESEARCH (NIR) OF NIVOLUMAB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PROGRESSING ON OR AFTER PLATINUM-BASED THERAPY

Genomic BRCA and Extensive ovArian cancer Testing

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

Psychological Experience of the End of the Treatment During a Clincal Trial of the Early Ohase and Role of the Initial prédispositions ( VRAIMENT)